Promoter Hypermethylation-Driven NPHS2 Silencing Promotes Immune Escape and Sunitinib Resistance in Clear Cell Renal Cell Carcinoma
Oncology Research · 2026
DOI: 10.32604/or.2026.080228 ↗Kurz gefasst
Fachartikel in der Zeitschrift Oncology Research, 2026. Verfasst von Shangjian Li und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, DNA Methylation, Promoter Regions, Genetic, Membrane Proteins. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Objective
Renal cell carcinoma is a common malignancy of the urinary system. In this study, we analyzed a public clear cell renal cell carcinoma (ccRCC) dataset and identified Nephrosis 2, idiopathic, steroid-resistant (NPHS2) as a candidate gene to investigate whether epigenetic dysregulation of NPHS2 is associated with tumor microenvironment remodeling.
Methods
Differential expression analysis was first performed on GSE68417 using GEO2R. In addition, clinical samples and cell-based assays were used to evaluate changes in NPHS2 expression and promoter methylation following 5'-Aza-CdR treatment. Subsequently, 786-O and A498 cells were obtained, and sunitinib-resistant 786-O/R and A498/R sublines were established. Lentiviral vectors with abnormal expression of NPHS2 were transfected into 786-O, A498, 786-O/R, and 498-R cells to detect changes in biological behaviors such as cell activity and epithelial-mesenchymal transition (EMT). Finally, a ccRCC tumor-bearing mouse model was constructed and intervened with lentiviral vectors with abnormal expression of NPHS2.
Results
A total of 159 differentially expressed genes (DEGs) were identified in the GSE68417 dataset, and NPHS2 was included in all morphological changes related to cell epigenetic modifications. 5'-Aza-CdR markedly increased NPHS2 protein expression in 786-O cells (p < 0.05). Meanwhile, there was a high methylation phenomenon in the promoter region of the NPHS2 gene in ccRCC tissue (p < 0.05). In vitro, NPHS2 overexpression suppressed malignant cell behavior, attenuated EMT, and weakened immune evasion in ccRCC cells (p < 0.05). Finally, upregulating NPHS2 could inhibit the growth of ccRCC (p < 0.05) without causing significant changes in liver and kidney functions or malignant pathological damage in mice.
Conclusion
These findings support an association between promoter hypermethylation and NPHS2 downregulation in ccRCC and suggest that NPHS2 loss may contribute to immune-evasive features and reduced sunitinib sensitivity. Further multicohort and mechanistic studies are warranted.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China.
- Department of Urology, Yiyuan County People's Hospital, Zibo, China.
- Department of Oncology, Guangrao County Traditional Chinese Medicine Hospital, Dongying, China.
Zitieren
APA
Li, S., Han, Q., Sun, X., & Yu, R. (2026). Promoter Hypermethylation-Driven NPHS2 Silencing Promotes Immune Escape and Sunitinib Resistance in Clear Cell Renal Cell Carcinoma. Oncology Research. https://doi.org/10.32604/or.2026.080228
Vancouver
Li S, Han Q, Sun X, Yu R. Promoter Hypermethylation-Driven NPHS2 Silencing Promotes Immune Escape and Sunitinib Resistance in Clear Cell Renal Cell Carcinoma. Oncology Research. 2026. doi:10.32604/or.2026.080228
BibTeX
@article{Li2026,
author = {Li, Shangjian and Han, Qipeng and Sun, Xinying and Yu, Rongrong},
title = {Promoter Hypermethylation-Driven NPHS2 Silencing Promotes Immune Escape and Sunitinib Resistance in Clear Cell Renal Cell Carcinoma},
journal = {Oncology Research},
year = {2026},
doi = {10.32604/or.2026.080228}
}
EUVIMED